CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer

Core Insights - CytoDyn Inc. announced new preclinical data indicating that leronlimab, a monoclonal antibody targeting the CCR5 receptor, enhances the effectiveness of standard therapies like temozolomide and radiation in treating glioblastoma multiforme (GBM) [1][2][3] Group 1: Leronlimab and Glioblastoma - Glioblastoma multiforme is characterized by a hypoxic and immunosuppressive tumor environment, leading to treatment resistance [2] - CCR5 expression in primary GBM tumors was significantly elevated compared to normal brain tissue and correlated with poor prognosis [6] - Inhibition of CCR5 with leronlimab showed functional synergy with temozolomide and enhanced radiation-induced cytotoxicity [6] Group 2: Clinical Implications - The findings support the initiation of a pilot study to evaluate leronlimab as an adjunct to standard-of-care therapy in glioblastoma [3][6] - The data presented at the AACR Special Conference highlights the potential role of CCR5 in overcoming resistance to standard therapies [2][3] Group 3: Company Overview - CytoDyn is focused on advancing leronlimab, which has shown a favorable safety profile and the ability to cross the blood-brain barrier in non-human primate models [5][8] - The company aims to improve patient quality of life through innovative therapeutic solutions targeting cancer and other diseases [8]